Autochecked users, Comment administrators, Editors, Interface administrators, Reviewers, Suppressors, Administrators, Widget editors
1,874
edits
Changes
no edit summary
Loss of function mutations and deletions affecting ''EZH2'' occur in 25% of T-cell acute lymphoblastic leukemia (Ntziachristos et al., 2012).
Loss of function mutations and deletions affecting ''EZH2'' occur in 25% of T-cell acute lymphoblastic leukemia (Ntziachristos et al., 2012).
'''[[Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]]'''
'''[[HAEM4:Acute Myeloid Leukemia (AML) and Related Precursor Neoplasms]]'''
''EZH2'' is highly expressed in AML, particularly in patients with complex karyotypes (Grubach et al., 2008), and is associated with extramedullary infiltration (Zhu et al., 2016). ''EZH2'' somatic mutations in AML are specific for secondary AML after an antecedent myeloid malignancy (Lindsley et al., 2015), although loss of ''EZH2'' attenuates leukemogenicity (Sashida et al., 2014; Tanaka et al., 2012). ''EZH2'' mutations are found with a frequency of ~2% in AML and are associated with lower blast percentage and -7/del(7q) karyotype, although they have no prognostic impact (Wang et al., 2013).
''EZH2'' is highly expressed in AML, particularly in patients with complex karyotypes (Grubach et al., 2008), and is associated with extramedullary infiltration (Zhu et al., 2016). ''EZH2'' somatic mutations in AML are specific for secondary AML after an antecedent myeloid malignancy (Lindsley et al., 2015), although loss of ''EZH2'' attenuates leukemogenicity (Sashida et al., 2014; Tanaka et al., 2012). ''EZH2'' mutations are found with a frequency of ~2% in AML and are associated with lower blast percentage and -7/del(7q) karyotype, although they have no prognostic impact (Wang et al., 2013).
'''[[Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)]], Myelodysplastic Syndrome, Myelofibrosis'''
'''[[HAEM4:Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN)]], Myelodysplastic Syndrome, Myelofibrosis'''
''EZH2'' is often overexpressed in myelodysplastic syndrome (MDS) (Xu et al., 2011). Mono- and biallelic ''EZH2'' inactivating mutations are found in 12% of myelodysplastic/myeloproliferative neoplasms and 13% of myelofibrosis (Ernst et al., 2010). They are associated with poor prognosis in myelofibrosis (Guglielmelli et al., 2011) and MDS (Bejar et al., 2011). Loss of ''EZH2'' promotes the development of myelodysplastic syndrome in a mouse model (Khan et al., 2013; Sashida et al., 2014).
''EZH2'' is often overexpressed in myelodysplastic syndrome (MDS) (Xu et al., 2011). Mono- and biallelic ''EZH2'' inactivating mutations are found in 12% of myelodysplastic/myeloproliferative neoplasms and 13% of myelofibrosis (Ernst et al., 2010). They are associated with poor prognosis in myelofibrosis (Guglielmelli et al., 2011) and MDS (Bejar et al., 2011). Loss of ''EZH2'' promotes the development of myelodysplastic syndrome in a mouse model (Khan et al., 2013; Sashida et al., 2014).